



Diagnostic stewardship

@BSACandJAC | @TheUrgentNeed

www.bsac.org.uk

Dr Nick Brown

Cambridge University Hospitals NHS Foundation Trust
Cambridge, UK

November 2019

Introduction – the clipboard audit



- Audits of antibiotic prescribing often assess compliance with a specific treatment guideline (e.g. UTI or community acquired pneumonia)
- An assumption is made that the original diagnosis was correct
- If you have got the diagnosis wrong, how can you prescribe the right treatment?



Limitations of current antibiotic prescribing

- Remains empirical (i.e. 'best guess')
- Diagnostic uncertainty compounded by antibiotic resistance
- Potential consequences:
 - Wrong organism targeted
 - Wrong antimicrobial agent selected
 - Unnecessary exposure to side effects
 - Expenditure without benefit

AMR Review by J O'Neill




What rapid diagnostics could test




Most use of antibiotics in humans is to treat an infection that they haven't got

Overuse of diagnostic tests




Adapted from: Morgan DJ et al. BMJ 2015; 351: h4534

PubMed citations with the term 'Diagnostic Stewardship' in the title field




Approach to diagnostic testing

Diagnostic stewardship view



Approach to diagnostic testing



Right test

Is the test appropriate for the clinical setting?


Right patient

Will the clinical care of the patient be affected by the test result?

Right time

Will the result be available in time to affect patient care optimally?

WHO Guide to Diagnostic Stewardship




Guide to support robust microbiological diagnosis, including antimicrobial susceptibility testing (AST) in countries participating in surveillance

<https://www.who.int>

WHO Essential Diagnostics List

Objectives



- In vitro diagnostics (IVDs) that are recommended for use in a tiered national health care system
- Not intended to be prescriptive
- Countries make own decisions based on national or regional burden of disease, unmet needs and priorities
- Informs UN agencies and NGOs that support selection, procurement, supply, donations or provision of IVDs.
- Informs medical technology private sector on IVD priorities and the IVDs needed to address global health issues.

<https://www.who.int>

WHO Essential Diagnostics List 2018

Primary health care

General IVDs

Urine dipstick and urine microscopy
Microscopy of disease appropriate specimens
(e.g. venous whole blood, urine, stool, etc.)

Disease-specific IVDs

Hepatitis B
HIV
Malaria
Tuberculosis
Syphilis

Health care facilities with clinical laboratories

General IVDs

Urine dipstick and urine microscopy
Culture of disease appropriate specimens (e.g.
venous whole blood, urine, stool, etc.)
Blood culture
Antimicrobial susceptibility testing

Disease-specific IVDs

Hepatitis B
HIV
Malaria
Tuberculosis
Syphilis

Approach to diagnostic testing

The traditional laboratory science view

Pre-analytical	Analytical	Post-analytical
Test selection Ordering Collection Transport	Processing Testing Test performance	Interpretation Reporting Intervention

Approach to diagnostic testing

The traditional laboratory science view

Pre-analytical	Analytical	Post-analytical
Test selection Ordering Collection Transport	Processing Testing Test performance	Interpretation Reporting Intervention

Diagnosing UTI





NICE

Urinary tract infection (lower) – women (Oct 2019)

- **If the woman is under 65y of age and does not have risk factors for complicated UTI, a urine dipstick can be used as an aid to diagnosis**
– dipstick is unreliable in women aged older than 65y and those who are catheterised
- **A sample should be sent for urine culture in all women with suspected lower UTI who:**
 - Are pregnant
 - Are older than 65y
 - Have symptoms that are persistent or do not resolve with antibiotic treatment
 - Have recurrent UTI (2 episodes in 6 months or 3 in 12 months)

To Dip Or Not To Dip?

- Project lead by Elizabeth Beech (Pharmacist)
- Project undertaken in 2015-16 to improve UTI management in Care Homes
- An audit in 2013 had shown that 115 of 347 residents had received 208 antibiotic prescriptions for UTI
- More than half were diagnosed on basis of urine dipstick testing
- Large number of prescriptions were for ciprofloxacin and cephalosporins

What did they do about it?

- Introduce an education bundle in care homes emphasising the limitations of using urine dipstick alone in assessing residents (23 care homes providing care for ~800 residents)
- Use NICE / SIGN 88 guideline to develop better, structured documentation for UTI diagnosis
- Monitor for unintended consequences
e.g. episodes of urosepsis requiring hospitalisation

Guidance for Care Home staff for older patients (>65) with a suspected UTI

- Complete and fax to GP surgery. File original in patient notes.
- **DO NOT PERFORM URINE DIPSTICK** – No longer recommended in pts >65 yrs
- CLEAR URINE – UTI highly unlikely
- Consider MSU where possible if ≥ 2 or more signs of infection - UTI likely

Patient:..... DOB:.....

Nursing Home:.....

Date:..... Carer:.....

Signs of any other infection source? Circle any new symptoms which apply:

Cough Shortness of breath Sputum production Nausea/vomiting Diarrhoea Abdominal pain Red/warm/swollen area of skin

Patients who can communicate symptoms:

NEW ONSET Sign/Symptom	What does this mean?	Tick if present
Dysuria	Pain on urinating	
Urgency	Need to pass urine urgently/new incontinence	
Frequency	Need to urinate more often than usual	
Suprapubic tenderness	Pain in lower tummy/above pubic area	
Haematuria	Blood in urine	
Polyuria	Passing bigger volumes of urine than usual	
Loin pain	Lower back pain	

Catheter?
Y / N

If YES:
Reason for catheter:

Temp / Perm

Date changed:

All Patients:

Sign/Symptom	Tick if present
Temperature above 38.3 or below 36 or shaking chills (rigors) in last 24 hours	
Heart Rate >90	
Respiratory rate >20	
Blood glucose >7.7	Diabetic? Y / N
Bloods taken?	WCC: CRP:
New onset or worsening confusion or agitation	

Management Decision:

- Review in 24 hours
- Mid Stream Urine specimen
- Antibiotic prescription for UTI: Nitrofurantoin (eGFR>45ml/min) Trimethoprim
- Other

Results



- **56% reduction** in the proportion of residents who had an antibiotic for a UTI



- **67% reduction** in the number of antibiotic prescriptions



- **82% reduction** in the number of residents prescribed antibiotic prophylaxis




- Reduction in unplanned admissions for UTI, urosepsis and acute kidney injury



- Reduced calls to GP practices for inappropriately diagnosed UTI

Educational bundle delivered to all nursing homes

Counts and 12-month rolling rates of E. coli bacteraemia by CCG and month - NHS Bath And North East Somerset CCG




Intervention to reduce treatment of urinary catheter–associated asymptomatic bacteriuria

Two outcomes studied:

- Decision to send a sample (unnecessary screening) and the decision to treat a positive result (overtreatment)

Main findings:

- Reduced sampling
- Decrease in treatment of asymptomatic bacteriuria 1.6 to 0.6/1,000 bed days
- No change in treatment of CAUTI



Selective urine culture and antibiotic utilisation


Reflex protocol in 500 ICU patients
Culture only if >10 wbc/hpf

Results:

- Fewer cultures
- Lower bacteriuria rates
- No change in overall antibiotic days of therapy (DOT)
- Fewer antibiotic starts for index urine culture


Pre: 55/134 (41%) vs.

Post: 28/123 (23%) ($p=0.002$)




Approach to diagnostic testing

The traditional laboratory science view



Working patterns: a standard 5 day lab service versus 7 day lab service

Turnaround Times for samples taken on different days of the week



The Bacteriology Laboratory


Cambridge laboratory c. 1987



Fleming's laboratory c. 1929



Levels of automation in bacteriology



The new Bacteriology Laboratory

Cambridge laboratory 2013



Allows us to store images

The screenshot shows the Breda software interface for MRSA screening. The main window displays four petri dish images with various analysis parameters and a 'No Image Available' placeholder. A 'New MRSA' dialog box is open over one of the dishes, showing analysis details. A status bar at the bottom indicates 'Ready for reading in future'.

MRSA Screening

SN: 09M159368 - MRSA Screening -

Analysis Parameters:

- CLED_1; C00000069739
- O2_ISO_1; C00000069738
- O2_ISO_1; C00000069737
- O2_ISO_1; C00000070649

New MRSA

Debes: 5

MRSA Follow ups

Analysis: 1008 DNase in O2 for 1 day; Media: DNase
 Analysis: 1029 ISO in O2 for 1 day; Media: Iso Sens; Template: MRSA1
 Analysis: 1082 Nutrient broth; Media: Nutrient Broth; Template: STAPH (S.aureus)
 Analysis: 1093 CLED in O2 for 1 day; Media: Cysteine Lactose Electrolyte Deficient

Barcode: C00000067185
 Description: MRSA in O2 for 18 hours
 Analysis Set: Brilliance Agar
 Media: Output stacker 1 buffer
 Workstation: <710002>- Container produced (28-10-2009 14:57:35)
 Flags:
 Status: Deleted

Message: Hint
 Making: New MRSA
 Specimen Requested: MRSS.PIF

30-10-2009 12:30:29 kasha Plate Reading ■ ■ ■ Ready for reading in future

Copyright © 2008, KESTRA Lab Automation

Record susceptibility test images and zone sizes



The screenshot displays the 'Image Viewer' software interface. On the left, a table lists the results for various antibiotic discs. The table has columns for 'Tablet name', 'Diameter', 'R', 'I', 'S', and 'Result'. The data rows are as follows:

Tablet name	Diameter	R	I	S	Result
CLP1	9 mm				
CLP20	32 mm	4	7	26	76
CLP2	34 mm	23			29
TEC30	18 mm	14			14
MS	16 mm	11			11
MS	27 mm	19			19

Below the table, there are icons for 'Fit Screen', 'Zoom In', 'Zoom Out', 'Previous Image', 'Next Image', 'Scanty Growth', 'Light Growth', 'Moderate Growth', and 'Heavy Growth'. A context menu is open over the table, showing options: 'Disconnect', 'Result = R', 'Result = I', 'Result = S', and 'Remove result'. The 'Result = I' option is currently selected.


The main window shows a petri dish with antibiotic susceptibility test results. The disc names and their corresponding zone diameters are visible on the dish: CLP1 (9 mm), CLP20 (32 mm), CLP2 (34 mm), TEC30 (18 mm), MS (16 mm), and MS (27 mm). The zones are highlighted with blue circles. Metadata at the top of the image area includes: Barcode: C00000069737, Date: 30/10/2009 08:22:00, and Scan: 0 / Nr: 1. At the bottom of the software window, the following information is displayed: 1624x1624, 094159368, C00000069737, Iso Sens, Black background.

MALDI-TOF Mass Spectrometry



Laser Desorption/Ionization


Time-of-Flight



Modified from: Lottspeich, Zorbas, eds
"Bioanalytik", Spektrum Akademischer Verlag, 1998



MALDI Biotyper - Workflow




TaqMan® Array Cards



1 to 8 samples


TaqMan®
Assays pre-
spotted

48 wells per
channel




384 wells (1µL reaction volume)

Respiratory Card: Version 9 – ECMO



- | | | | |
|--|---|---|--|
| <ol style="list-style-type: none"> 1. RSV A 2. RSV B 3. HPIV 1 4. HPIV 2 5. HPIV 3 6. HPIV 4 7. Enterovirus 8. Rhinovirus 9. B. pertussis ptx S1 10. HCoV OC43/HKU1 11. 18S RNA 12. HCoV NL63 13. HCoV 229E 14. hMPV 15. MS2 IC 16. Adenovirus #1 17. Bocavirus 18. Adenovirus #2 19. L. pneumophila 20. M. pneumoniae 21. C. pneumoniae 22. Coxiella burnetii 23. C. psittaci 24. M. tuberculosis | <ol style="list-style-type: none"> 25. Flu B #1 26. Flu B #2 27. Staph PVL 28. Flu A #2 29. Flu A #3 30. S. pneumoniae#1 31. S. pyogenes#1 32. S. aureus (Nuc) 33. Aspergillus 28S 34. Flu A H12009 35. Flu A H3 36. Legionella species#1 37. H. influenzae #1 38. Enterovirus Br 39. M. pneumoniae #2 40. B. pertussis IS481 41. Parechovirus 42. P.jiroveci #1 43. RSV #3 44. HCoV OC43 45. Rnase P IC 46. HPIV 1 #2 47. HPIV 3 #3 48. Rhinovirus #2 | <ol style="list-style-type: none"> 49. HSV#1 50. HSV#2 51. HSV#3 52. HSV type 1 53. HSV type 2 54. EBV#1 55. EBV#2 56. VZV#1 57. VZV#2 58. CMV#1 59. CMV#2 60. BK#1 61. BK#2 62. BK/JC 63. Aspergillus 28S 64. Measles#1H 65. Measles#2 N 66. Legionella spp # 5a 67. Tamiflu S 68. Tamiflu R 69. IS481#2 70. L. pneumophila #2 71. S. pneumoniae #2 72. H. influenzae #2 | <ol style="list-style-type: none"> 73. S. pyogenes# 2 74. N. meningitidis 75. Mec A 76. S. aureus (Nuc) 77. TB#2 78. TB#3 79. P.jiroveci #2 80. P.jiroveci #3 81. MS2 IC 82. EVD68 83. Acanthamoeba #1 84. Acanthamoeba #2 85. Fusarium #1 86. Fusarium #2 87. A. fumigatus new 88. B19 89. MERS #1 90. MERS #2 91. MERS #3 92. Leptospirosis #1 93. Legionella spp # 6a 94. Legionella species #2 95. Legionella species #3 96. Legionella spp # 4a |
|--|---|---|--|

TaqMan[®] Array Cards: Process



20µL NA
 25µL Master Mix
 (Fast Virus 1 step)
 55µL Water

1200 rpm / 2 mins

50°C 5 min (RT)
 95°C 20 sec
 95°C 1 sec } X 45
 60°C 20 sec }


Approach to diagnostic testing

The traditional laboratory science view

Pre-analytical	Analytical	Post-analytical
Test selection Ordering Collection Transport	Processing Testing Test performance	Interpretation Reporting Intervention


Selective antibiotic reporting

Clinical case histories presented to GPs



Selective antibiotic reporting

Change in reported antibiotic susceptibilities and impact on GP prescribing



O'Neill update July 2019



10 areas, 29 recommendations

Progress in:

- R&D and investment in AMR
- Early development of new compounds

Lack of progress in:

- Big Pharma engagement and investment
- Diagnostics